1.Effects of short-term structural psychological education on depression and immunity in patients with Barcelona clinic liver cancer B or C stage hepatocellular carcinoma
Xinhua ZHAO ; Lingyun ZHAO ; Jueling WEI ; Mei LUO ; Xuemei YOU
Chinese Journal of Modern Nursing 2019;25(14):1764-1768
Objective? To explore the effects of short-term structural psychological education on depression and immunity in patients with Barcelona clinic liver cancer B or C stage (BCLC-B/C) hepatocellular carcinoma. Methods? Totally 210 patients with BCLC-B/C hepatocellular carcinoma who were admitted in the Department of Hepatological Surgery, Guangxi Medical University Affiliated Tumor Hospital from June 2016 to March 2018 were selected by convenient sampling and divided into the non-depression group (n=79) and the depression group (n=131) according to Hospital Anxiety and Depression Scale-Depression (HADS-D) and Patient Health Questionnaire (PHQ-9). Patients in the depression group were randomly divided into the intervention group (n=66) and the control group (n=65). Patients in the non-depression group and the depression-control group received conventional nursing care, while patients in the depression-intervention group received short-term structural psychological education on the basis of conventional nursing care. HADS-D, PHQ-9 and cytoimmunity indexes were used to evaluate the effects of intervention. Results? The HADS-D and PHQ-9 scores of the depression-intervention group were lower than those of the control group on day 30 postoperatively(P<0.01). The CD3+, CD3+CD4+, CD3+CD4+/CD3+CD8+ levels of the depression-intervention group were higher than those of the depression-control group on day 30 postoperatively (P<0.05). Conclusions? Short-term structural psychological education can effectively improve the depression and immunity in patients with BCLC-B/C,which is worth promoting in clinical practice.
2.Changes of serum CRP and hs-CRP levels in patients with liver cancer and depression and their influence on prognosis
Fengjuan ZHAO ; Qi WANG ; Yunhong REN ; Jueling WEI ; Lequn LI ; Xinhua ZHAO ; Juan TANG ; Xuemei YOU
Practical Oncology Journal 2019;33(1):27-33
Objective The objective of this study was to investigate the effect of depression on serum levels of C-reactive protein(CRP)and high-sensitivity C-reactive protein(hs-CRP),and prognosis in liver cancer patients. Methods A total of 251 patients with liver cancer undergoing hepatectomy were enrolled. The hospital anxiety and depression scale( HADS-D) and 9-item patients health questionnaire(PHQ9) were assessed for depression before 3 days for surgery. Patients were divided into depression group(n=95)and non-depression group(n=156) according to the scores. Preoperative serum levels of CRP,hs-CRP,ALT and AST were measured and compared between the depression and non-depression groups. Survival analysis Kaplan-Meier method was used to compare the disease-free survival(DFS)and total survival(OS)between the two groups. Results The serum levels of CRP, hs-CRP,ALT and AST in the depression group were significantly higher than those in the non-depression group(P<0. 05). The follow-up of 3. 5-year showed that 164 patients(65 in depression group and 99 in non-depression group)had recurrence or metas-tasis and 47 patients(22 in depression group and 25 in non-depression group) died. The DFS and OS in the depression group were significantly lower than those in the non-depression group(P< 0. 05). Cox multiple regression analysis showed that liver function grading,BCLC staging and depression were independent risk factors for the prognosis of liver cancer. Spearman correlation analysis showed that patients′degree of depression was positively correlated with serum levels of CRP and hs-CRP(P<0. 05),DFS and OS were negatively correlated with serum levels of CRP and hs-CRP(P<0. 05). Conclusion Depression may mediate elevated serum levels of CRP and hs-CRP,maintain inflammatory response in patients,lead to increased liver function damage,elevate levels of ALT and AST,and thus adversely affect the prognosis of patients with liver cancer.